Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
Pulmonary alveolar microlithiasis (PAM) is caused by genetic variants in the <i>SLC34A2</i> gene, which encodes the sodium-dependent phosphate transport protein 2B.
|
31831582 |
2020 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
Biallelic inactivating SLC34A2 mutations are found in patients with pulmonary alveolar microlithiasis, a lung disease characterized by the deposition of microcrystals.
|
30542787 |
2019 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
A mutation in the IIb sodium phosphate transporter SLC34A2 gene has recently been described in pulmonary alveolar microlithiasis (PAM) patients.
|
29375690 |
2018 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GermlineCausalMutation
|
disease |
ORPHANET |
SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures.
|
23164546 |
2013 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
SLC34A2 Gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures.
|
23164546 |
2013 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
We present two cases of pulmonary alveolar microlithiasis with different mutations in the SLC34A2 gene that have not been previously described, and a review of the literature.
|
22941890 |
2012 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GermlineCausalMutation
|
disease |
ORPHANET |
A frame-shift mutation in the SLC34A2 gene in three patients with pulmonary alveolar microlithiasis in an inbred family.
|
20046000 |
2010 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
A case of pulmonary alveolar microlithiasis with an intragenetic deletion in SLC34A2 detected by a genome-wide SNP study.
|
19329736 |
2009 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the SLC34A2 gene that abolish normal gene function cause pulmonary alveolar microlithiasis.
|
17095743 |
2007 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
BEFREE |
Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis.
|
16960801 |
2006 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
GeneticVariation
|
disease |
UNIPROT |
Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis.
|
16960801 |
2006 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Inherited interstitial lung disease.
|
15331184 |
2004 |
Pulmonary Alveolar Microlithiasis
|
0.780 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Pulmonary Alveolar Microlithiasis
|
0.780 |
Biomarker
|
disease |
CTD_human |
|
|
|
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Correction to: The effects and mechanisms of SLC34A2 in tumorigenesis and progression of human non-small cell lung cancer.
|
30755199 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Our data suggested MEG3 was involved in stem cell-like state of LCCs and curbed migration and invasion through miR-650/SLC34A2 axis in NSCLC.
|
31585300 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
The fusion gene SLC34A2-ROS1 (solute carrier family 34 member 2 and ROS proto-oncogene 1) plays an important role in non-small cell lung cancer (NSCLC) progression.
|
31118036 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Publicly available NSCLC cell lines harboring the ROS1 fusion gene are limited to only HCC78 cells carrying SLC34A2-ROS1.
|
29738763 |
2018 |
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Dysregulation of SLC34A2 (NaPi2b) in tumors has attracted wide attention, but its expression and function in non-small cell lung cancer remains unclear.
|
28720066 |
2017 |
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Hence, our data for the first time delineated that unusual expression of SLC34A2 was modulated by miR-410, and miR-410 might positivelycontribute to the tumorigenesis and development of NSCLC by down-regulating SLC34A2 and activating Wnt/β-catenin signaling pathway.
|
26910912 |
2016 |
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found that expressions of SLC34A2 were reduced in six NSCLC cell lines for the first time.
|
26156586 |
2015 |
Non-Small Cell Lung Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The expressed ROS1-SLC34A2 and CCDC6-RET gene fusions from the NSCLC cell lines HCC78 and LC-2/ad, respectively, were accurately detected by the novel assay.
|
25384172 |
2015 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
We selected NSCLC cell lines--A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concentrations of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.
|
22617245 |
2012 |
Non-Small Cell Lung Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
|
22919003 |
2012 |
Drug toxicity
|
0.300 |
Biomarker
|
group |
CTD_human |
Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers.
|
15805072 |
2005 |